The growing interest in applying nanotechnology to cancer is largely attributable to its uniquely appealing fea tures for drug delivery, diagnosis and imaging, synthetic vaccine development and miniature medical devices, as well as the therapeutic nature of some nanomaterials themselves [1] [2] [3] [4] [5] [6] 
. Nanotherapies that incorporate some of these features (for example, improved circula tion and reduced toxicity) are already in use today, and others show great promise in clinical development, with definitive results expected in the near future. Several therapeutic nanoparticle (NP) platforms, such as lipo somes, albumin NPs and polymeric micelles, have been approved for cancer treatment, and many other nano technologyenabled therapeutic modalities are under clinical investigation, including chemotherapy, hyper thermia, radiation therapy, gene or RNA interference (RNAi) therapy and immunotherapy (TABLE 1) .
Along with enormous progress in the field of can cer nanomedicine (FIG. 1) , we have also gradually real ized the challenges and opportunities that lie ahead. Foremost, the complexity and the heterogeneity of tumours make it clear that careful patient selection is required to identify those most likely to benefit from a given nanotherapy. This is analogous to the targeted therapies approved or under development for use in specific biomarkerdefined patient populations. Most therapeutic NPs for solid tumour treatment are admin istered systemically; they accumulate in the tumour through the enhanced permeability and retention (EPR) effect [7] [8] [9] [10] , which is generally thought to be the product of leaky tumour vasculature and poor lymphatic drain age. However, this interpretation of EPR is somewhat oversimplified, as multiple biological steps in the sys temic delivery of NPs can influence the effect, such as NP-protein interaction, blood circulation, extra vasation into and interaction with the perivascular tumour microenvironment (TME), tumour tissue pene tration and tumour cell internalization. In turn, NP properties (for example, size, geometry, surface features, elasticity, stiffness, porosity, composition and targeting ligand) can influence these biological processes, thus deter mining the EPR effect and therapeutic outcomes (FIG. 2) . Nevertheless, it is important to point out that most of our current understanding of NP behaviour in vivo is based on animal data, and its translation to NP behav iour in humans remains largely unexplored. Although several studies have examined the pharmaco kinetics (PK) of nanotherapeutics across species in preclinical and clinical studies [11] [12] [13] , relatively few have correlated data across species to determine whether and how NP safety and efficacy in humans can be better predicted from preclinical animal models.
This Review aims to identify gaps in our under standing of why cancer nanomedicine has yet to fulfil its promise in prolonging patient survival, and to offer an overview of our current grasp of tumour biology and nano-bio interactions as they relate to maximization of the impact of cancer nanotherapeutics. Given the presumed crucial role of EPR, we present recent pro gress in exploring this effect and identifying markers to predict responses to nanotherapies, and in develop ing new strategies to enhance systemic NP delivery for more pronounced EPR and therapeutic benefit. We also examine the fundamentals behind the development of
Enhanced permeability and retention (EPR) effect
The mechanism resulting from pathophysiological processes (for example, leaky tumour vasculature, poor lymphatic drainage and tumour microenvironment interactions) that leads to the accumulation and retention of nanoparticles or macromolecules in tumours.
Nano-bio interactions
The interactions between nanoparticles and biological systems (for example, serum proteins, extracellular matrix, cells and organelles) that determine the biological fates of nanoparticles, such as circulation half-life, biodistribution, tumour accumulation, tumour cell internalization and tumour microenvironment distribution.
Excipients
Substances other than the active pharmaceutical ingredient (API) that are included in the manufacturing process of a medication or are contained in a finished pharmaceutical product dosage form.
C max
The maximum serum concentration that a drug or nanoparticle achieves after administration.
nanotechnologies to target the TME, which has such an important role in tumour progression and metastasis 14, 15 , and lastly, provide our perspective on challenges to the clinical translation of cancer nanomedicines.
Arsenal of nanomedicine platforms
Nanotechnology has made important contributions to oncology over the past several decades (FIG. 1; TABLE 1 ). Liposomes (for example, liposomal doxorubicin (LD); Doxil and Myocet) were the first class of therapeutic NPs to receive clinical approval for cancer treatment 16 , and along with other lipidbased NPs, still represent a large proportion of clinicalstage nanotherapeutics. Although encapsulating drugs in liposomes has been broadly shown to improve PK and biodistribution, as yet no marketed liposomal therapeutic agents have exhib ited an overall survival (OS) benefit when directly com pared with the conventional parent drug 17 . The recent phase III results of liposomal cytarabine-daunorubicin (Vyxeos; also known as CPX351) compared with the standard of care regimen of cytarabine and dauno rubicin in patients with highrisk acute myeloid leu kaemia, showed improved OS of 9.56 months versus 5.95 months 18 . This is encouraging for the field of can cer nanomedicine and regulatory filing for the approval of Vyxeos is projected in late 2016. NP albuminbound paclitaxel (nab paclitaxel; Abraxane) was the second class of nanomedicines to be commercialized. The nab platform enables formulation of hydrophobic drugs while largely mitigating the need to use toxic excipients. The result may be a bettertolerated drug that can be used at higher doses and administered more quickly, thus enabling a higher drug C max and plasma area under the curve (AUC). Upon intravenous infusion, nab paclitaxel rapidly dissociates into its albumin and paclitaxel constituents and has not been demon strated to substantially alter the PK and biodistribution of paclitaxel. Although the every3week dosing sched ule of nabpaclitaxel is superior to paclitaxel in terms of response rate and time to progression for patients with breast cancer 19 , a onceperweek dosing schedule did not show similar trends in progressionfree survival (PFS) or OS and furthermore, showed increased tox icity 20 . More intriguingly, our understanding of nano-bio interactions and the arsenal of nanomedicine platforms are expanding rapidly. The total number of papers related to 'nanoparticle' on PubMed nearly doubled every 2 years between 2000 and 2014, surpassing the remarkable rise of the number of publications on 'mono clonal antibody' (mAb) in the 1980s. In the case of mAb this translated to the development of important thera peutics, and we expect a similar transformative impact from the rise of nanomedicine in the years to come.
Beyond their widely reported use as carriers for chemo therapeutics, NPs have shown potential for the delivery of various new anticancer therapeutic agents, including molecularly targeted agents 24 , antisense oligo nucleotides 28, 29 , small interfering RNA (siRNA) [30] [31] [32] [33] , mRNA 34 and DNA inhibitor oligonucleotides 35 . Further more, the use of viral NPs for therapeutic delivery has been facilitated by genetic and chemical engineer ing techniques 36 . Examples include the use of adeno associated virus, approved by the European Commission for lipoprotein lipase deficiency 37 , lentivirus currently in various clinical trials for cellbased gene therapy and immunotherapy of various diseases including cancer 38 , and engineered plant viruses (for example, tobacco mosaic virus and potato virus X) for cancer therapy in animal models 39, 40 . With their endo genous origin and organ tropism, exosomes have also been proposed for carrying anticancer payloads to target tumours 41 . Lastly, novel inorganic NPs such as nano diamond 42, 43 and graphene 44, 45 have received considerable attention for cancer therapy.
We are also already seeing indepth innovation in nanomedicine strategies. By integrating diagnostic and therapeutic functions into a single NP formulation, theranostic nanomedicine offers a promising strategy to monitor the PK and accumulation of therapeutics and the progression of disease, giving important insights into heterogeneities both within tumours and between patients for potential personalized treatment 46, 47 . By codelivering multiple active pharmaceutical ingre dients (APIs), NPs have also facilitated synergistic 
Payloads
The therapeutic or diagnostic agents carried by nanoparticles.
by antigenpresenting cells, sustained release of antigens or adjuvants and NPmediated phagosome escape of antigens for crosspresentation 4, [48] [49] [50] . Nanotechnology may also hold great potential for addressing the shortcomings associated with biologics, including mAbs that are used for cancer immunotherapy. For example, the administration of biologic drugs can induce the formation of antidrug antibodies (ADAs) that may adversely affect their safety and efficacy 51 . Recently engineered tolerogenic NPs carrying rapamycin were shown to abolish the formation of ADAs for biologics in mice and nonhuman primates 52 , and human clinical trials are currently ongoing 53 . Our expectation is that by gaining a deeper insight into nano-bio interactions and the personalization of nanomedicines, and through the application of nanotechnology to existing and emerging therapeutic modalities, we will begin to realize the true potential of nanomedicine in cancer and beyond.
The EPR effect in predictive nanomedicine Despite efforts to develop noninvasive administration (for example, oral, pulmonary, nasal and transdermal) of NPs [54] [55] [56] , most cancer nanotherapeutics are delivered intravenously for systemic transport to tumours. The preferential accumulation of NPs in tumours is gener ally ascribed to defective tumour vessels and impaired lymphatics in the tissue: enhanced permeability of the abnormal tumour microvasculature enables NPs to enter the tumour interstitial space, while suppressed lymphatic drainage causes retention within the tissue. The EPR effect [7] [8] [9] [10] has become the foundation of NP delivery to solid tumours. Nevertheless, it is increas ingly clear that EPR varies substantially between both patients and tumour types, and even within the same patient or tumour type over time. However, little effort has been made to address the effect of EPR on nano therapeutic efficacy. Several preliminary clinical studies have already suggested the value of stratifying subpopu lations of cancer patients according to their likelihood of accumulating NPs through EPR [57] [58] [59] , implying that pre dictive markers for EPR may have a role in the clinical success of cancer nanotherapies.
In our previous review of EPR 9 , we discussed the parameters of the TME, some of which are well charac terized for their interactions with NPs, whereas others are considered a 'black box' requiring extensive investi gation. Recently, there has been growing emphasis on the role of tumourassociated macrophages (TAMs) in NP-TME interactions [60] [61] [62] [63] . TAMs have also been proposed as a reservoir of nanotherapeutics from which the payload is gradually released to neighbouring tumour cells 62 . Using highresolution intravital imaging microscopy, a recent work systematically studied the extravasation and intratumoural distribution of two different types of NP 63 : the clinically approved 30 nm magnetic NP (MNP) ferumoxytol 64 and a 90 nm poly meric NP composed of poly(d,llacticco glycolic acid)bpoly(ethylene gly col) (PLGAPEG) 11, 65, 66 . Despite differences in both size and composition, MNP and polymeric NP exhibited similar PK after simultaneous intravenous injection, and co localized to varying degrees in cancer cells and TAMs. Furthermore, after coadministration of MNPs and docetaxelencapsulated PLGAPEG NPs, tumour MNP levels showed a significant correlation with NP payload levels. Consequently, the MNP accumulation level successfully predicted the anticancer efficacy of the thera peutic polymeric NPs. A pilot clinical study was also recently initiated to assess ferumoxytol as a marker to predict tumour response to the nano liposomal irinotecan MM398 (REFS 57,61,67 of lesion size reduction in six cancer patients suggests a positive association with ferumoxytol levels in the lesions at 24 hours 57 , although a larger study is required for validation. We expect further similar findings to pave the way for companion imaging particles, such as feru moxytol, to be used in patient selection and predictive nanomedicine (FIG. 3a) .
Therapeutic NPs labelled with radioisotopes (for example, 111 In, 99m Tc, 123 I and 64 Cu) have also been used to monitor biodistribution and tumour accumu lation through noninvasive imaging techniques that include singlephoton emission computed tomography (SPECT), computed tomography (CT) and positron emission tomography (PET) 58, 59, [68] [69] [70] [71] . A recent clinical study demonstrates that high tumour accumulation of LD as determined by quantitative imaging of [ 99m Tc]LD, is positively associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of LD and cisplatin 59 . A high degree of heterogeneity in tumour accumulation was also revealed by PET-CT imaging of 64 Culoaded liposomes in canine cancers, with six of seven carcinomas com pared with only one of four sarcomas displaying high uptake of liposomes 72 . These results highlight the poten tial of radioisotopelabelled therapeutic NPs to assess patient suitability for nanotherapies (FIG. 3b) . Although incorporation of contrast agents in therapeutic NPs can provide important insights into tumour heterogeneities and EPR, the development of such theranostic NPs may pose additional complexity in terms of design, synthesis, scaling and regulatory considerations 47 .
Aside from developing imaging NPs as potential mark ers of therapeutic efficacy, few studies have aimed to identify EPRpredictive gene, protein or cell biomarkers (FIG. 3c) . The ratio of matrix metallo proteinase 9 (MMP9) to tissue inhibitor of metalloproteinase 1 (TIMP1) in the circulation, as well as vessel wall collagen content, has been shown to predict EPR for liposomes 73, 74 . Various cir culating biomarkers associated with angiogenesis, such as angiogenic factors (for example, vascular endothelial growth factor A (VEGFA), fibroblast growth factor 2 (FGF2), MMP9, interleukin8 (IL8), IL6 and hepatocyte Figure 2 | The impact of nanoparticle properties on systemic delivery to tumours. Nanoparticles (NPs) can be made from different materials and have various physicochemical properties (for example, size, geometry, surface features, elasticity and stiffness, among others) and can be modified with a myriad of targeting ligands of different surface density (part a). NP properties affect the biological processes involved in the delivery to tumour tissues, including interactions with serum proteins (part b), blood circulation (part c), biodistribution (part d), extravasation to perivascular tumour microenvironment through the leaky tumour vessels and penetration within the tumour tissue (part e), and tumour cell targeting and intracellular trafficking (part f). NPs can also be designed to control the release profile of payloads (part g). ID, injected dose. IL, interleukin; MCL1, myeloid cell leukaemia 1; MoS 2 , molybdenum sulfide; mi RNA, microRNA; MRP1, multi-drug resistance-associated protein 1 (also known as ABCC1); NPs, nanoparticles; NSCLC, non-small-cell lung cancer; RNAi, RNA interference; SCLC, small-cell lung cancer; siRNA, small interfering RNA; TGFβ, transforming growth factor-β; TRAIL, tumour necrosis factor (TNF)-related apoptosis-inducing ligand; VEGFA, vascular endothelial growth factor A.
Opsonins
Plasma proteins (for example, immunoglobulins, complement proteins and fibrinogen) that coat a foreign particle to facilitate its uptake and destruction by phagocytic cells.
Mononuclear phagocyte system
(MPS). Part of the immune system composed of scavenging monocytes and macrophages, located in reticular connective tissue surrounding, for example, the liver, spleen, lung and bone marrow.
growth factor (HGF)), proteins and peptides (for exam ple, endostatin and tumstatin), and endothelial cells and endothelial progenitor cells, have been described 75, 76 . However, their role, along with other potential bio markers in predicting EPR, needs further investigation in preclinical and correlative clinical studies.
Enhancing drug delivery to the tumour NP-protein interactions. When a NP enters a biologi cal environment (for example, blood, interstitial fluid or extracellular matrix (ECM)), its surface is rapidly cov ered by various biomolecules (typically proteins), leading to the formation of a 'corona' (REFS 77-81) (FIG. 2b) . The adsorption of proteins alters the particle size, stability and surface properties and, more importantly, provides the NPs with a biological identity that determines the physio logical responses they elicit, ranging from cellular uptake and intracellular trafficking to PK, biodistribution and toxicity (FIG. 2c-f) . For instance, the binding of opsonins can trigger recognition and clearance by the mononuclear phagocyte system (MPS) 79 . Conversely, it has also been suggested that a corona rich in dysopsonin proteins (for example, apolipoproteins and albumin), which inhibit phagocytic uptake, could contribute to the stealth effect of NPs [82] [83] [84] . While ligandfunctionalized NPs might lose targeting capability when a protein corona forms on their surface 85 , decoration of NPs with some particular plasma proteins could improve delivery to specific organs. One recent example is the finding that apolipoprotein E is essential for some siRNA lipoplexes to target hepatocytes in vivo 86 . In contrast, NP-protein interactions in clini cal settings can also trigger hypersensitivity reactions in patients by activating the complement system 87 . Using various analytical techniques, several studies have extensively characterized the protein corona (for example, its composition, density, conformation, thick ness, affinity and dynamics) on certain nanomaterials (for example, gold, silica and polystyrene NPs and lipo somes) 88 . It is now clear that NP-protein interactions are highly dependent on the NP physicochemical properties, exposure time as well as protein source and concentra tion. However, we still do not have a clear picture of how NP properties (FIG. 2a) and protein adsorption patterns (FIG. 2b) correlate with specific physiological responses (FIG. 2c-f 90 . Attention was also paid to the crucial role of human disease type on the composition of the protein corona and its effects on cellular uptake and toxicity of NPs 91 . Nevertheless, most of these studies were focused on NP-protein inter actions in vitro, and little effort has been made to study protein corona formation in vivo and its correlation with PK, biodistribution and therapeutic efficacy. It is note worthy that the very few in vivo evaluations of the pro tein corona demonstrated significant differences between in vitro and in vivo results
92
. Moreover, we think that this field could be further advanced by addressing the following questions. Do we need specific proteinknockout mouse models to vali date and explain the observations from in vitro studies and normal mice? In addition to the widely studied pro teins in serum, how do the proteins in other biological environments, such as the TME, affect the corona, NP interactions with tumour cells and NP penetration across the tumour ECM? What new techniques will we need to more precisely characterize and quantify the in situ pro tein corona? We expect that by extending the methodo logy of quantitative structure-activity relationships to diverse NP platforms and biological responses, such nanomics approaches could facilitate a deeper under standing and better control of the nano-bio interface and prompt more rational design of safe, effective and even patientspecific nanomedicines. 
Nanomics
The collective study and characterization of the interactions between nanomaterials and biological systems.
Circulation half-life
The period required for drugs or nanoparticles in the blood to be reduced by one-half of a given concentration or amount.
Oncotic pressure
A form of osmotic pressure exerted by colloids in a solution, such as proteins in the plasma of a blood vessel.
Blood circulation. There is a relationship between blood circulation half-life (FIG. 2c) and the efficiency with which a NP passively extravasates from the microvasculature into the TME. For tissues with relatively large blood flow and particles that efficiently extravasate from the micro circulation, a relatively short blood circulation halflife may be sufficient for the desired accumulation in the tumour. Conversely, for poorly perfused tissues or par ticles with low extravasation efficiency, a longer circula tion halflife may be necessary to enhance exposure in the tumour microvasculature, enabling extravasation to occur progressively. One major factor limiting circulation time is the non specific interaction between NPs and serum proteins discussed above, which can promote opsonization and recognition by the MPS. Among various approaches to developing longcirculating NPs, the most widely used is PEG grafting on to the NP surface 93, 94 , such as Doxil, a 'stealth liposome' with a circulation halflife of approxi mately 2 days 95 . Although pegylation can reduce protein adsorption through hydrophilicity and steric repulsion effects to avoid MPS clearance, such a simplistic view of 'stealth' longcirculating particles, which was coined more than 25 years ago ('Stealth' being a trademark of Liposome Technology, Inc., Menlo Park, California, USA), is becoming outdated. For example, increasing the density of PEG on a gold NP surface can decrease the amount and change the types of protein that bind to the NPs, reducing macro phage uptake in vitro 82 . More recently, pegylation of poly styrene NPs has been shown to selectively enrich the adsorption of clusterin to the NP surface, contributing to the decreased nonspecific macro phage uptake in vitro 96 . The mechanical stiffness and elasticity of particles has also been recognized to influence MPS sequestration 97, 98 . Another biologically inspired strategy to extend resi dence time in blood is to modify NPs with 'self ' markers that prevent normal cells from activating the MPS. The bottomup approach is chemical conjugation of self mark ers such as CD47 peptides 99 to the NP surface, which can inhibit phagocytosis. The topdown method is to coat NPs with a membrane of erythrocytes, leukocytes or thrombocytes, thus 'camouflaging' them to help reduce MPS elimination [100] [101] [102] [103] . Although the circulation halflife of cell membranecoated NPs is longer than that of 'bare' NPs, it is still much shorter than that of the cells them selves. Therefore, more efforts are required to examine the changes in the cell membrane, including its components and elasticity, after the NP surface has been coated.
Extravasation to the TME. Extravasation of NPs from the systemic circulation to tumours (FIG. 2d,e) can be influ enced by aberrant tumour vasculature, the perivascular TME and the NP itself. The metabolic demands of rap idly dividing cancer cells result in the formation of neo vasculature that is architecturally abnormal and exhibits a 'leakiness' distinct from that occurring with inflamma tion. Unlike the endothelial lining of normal vasculature, which has a turnover of approximately 1,000 days, the endothelium in tumours can double approximately every 10 days 104 , and the resulting microvasculature does not have clearly defined morphology with distinct venules, arterioles or capillaries. In the case of inflammation, the extravasation of immune cells occurs primarily at the level of the venules 105 . However, the exact contribu tion of various segments of the tumour neovasculature to permeability remains poorly understood. In addition to an arsenal of inflammatory mediators such as hista mine 106, 107 , the interaction of tight junction modulators such as cationic polymers with endothelium can also induce endothelial contraction and tight junction dis assembly, leading to vascular leakiness 108 . For tumours, both vascular permeability and blood velocity are com plex and kinetically variable from segment to segment 109 . The spatiotemporal changes in vascular permeability can also be in part explained by the recent observation of transient opening and closing of pores, referred to as 'dynamic vents' , in the walls of tumour vessels 110 . With an adequate NP circulation halflife, the dynamic vents could potentially improve delivery to tumours (in particular for large NPs). Furthermore, vascular mediators such as nitric oxide and angiotensin II could enhance tumour vascu lar permeability for more effective NP extravasation 10, 111 . There is also considerable variability in blood viscosity and oncotic pressure in various segments of the vasculature and TME, influencing the movement of NPs into and out of the tumour interstitium. Further studies will help to elucidate the mechanisms involved in NP extravasation into tumours, improving engineering and design schemes for efficient NP accumulation.
The impact of NP physicochemical properties on tumour extravasation and accumulation has also been examined. For example, in hyperpermeable murine colon adenocarcinoma, 30, 50, 70 and 100 nm poly meric micelles all demonstrated similar extravasation and anticancer activity, whereas in hypopermeable pan creatic tumours, only the 30 nm micelles showed suffi cient accumulation 112 . This study further indicates the influence of tumour heterogeneity on nanotherapeutic efficacy, underscoring the need for personalized nano medicine. Compared with nanospheres, some elongated nano structures (for example, the nanoworm 113 and the nanorod 114 ) improve tumour accumulation. Non spherical particles also tend to accumulate and adhere to the endothelial cells that line vessel walls better than spherical or quasihemispherical particles, enhancing site specific delivery 115, 116 . However, the effect of NP shape on extravasation can be very complicated, depending on the tumour models studied 117 . Other unique strategies have also been proposed to enhance extravasation of NPs to the tumour interstitial space. Exploiting the 'tumourtropic' property of certain cells (for example, mesenchymal stem cells, macrophages and monocytes) [118] [119] [120] [121] , therapeutic NPs can either be attached to the cell surface or loaded into the cells for homing to tumours. Recently, an innovative approach used two types of communicating NP to amplify tumour targeting and accumulation 122 : the photothermal heating of 'signalling' gold nanorods disrupts tumour blood ves sels to initiate extravascular coagulation, which can be recognized by the 'receiving' NPs in circulation, which bind to the resulting clot.
Tumour penetration. Despite the emphasis on extra vasation and accumulation in NP delivery, it is now known that, depending on the therapeutic payload, deep and uniform tumour penetration of nanotherapeu tics may also be crucial for optimal outcomes. Studies of macr molecules (for example, dextrans 123 and anti bodies 124 ) demonstrate that size and binding affinity affect both diffusion kinetics and depth of tissue pen etration. For instance, higher affinity antibodies that bind to target antigens on cancer cells penetrate tissue less efficiently than loweraffinity antibodies against the same target
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. This is because during tissue penetration higheraffinity antibodies tend to bind tightly to the target and become internalized, whereas loweraffinity antibodies tend to bypass their target and thus penetrate deeper. Much can be learned from antibody studies to aid in the design of nanotechnologies for cancer target ing, such as the pros and cons of adding targeting ligands on the NP surface 47 ; although this may enhance cellular uptake and lengthen tissue residence, it may also reduce the depth of tumour penetration.
Therapeutic NPs, nearly always larger than anti bodies, tend to become trapped in the ECM around the micro vessels from which they extravasate 125 (FIG. 2e) . Challenges include the physiological barriers intrinsic to the TME, such as the dense interstitial matrix composed of colla gen fibres and other proteins, and the elevated inter stitial fluid pressure (IFP) induced by hyper permeability of abnormal vasculature and lack of functional lymphatics deep in the tumour tissue 125, 126 . These in turn reduce con vective transport of NPs across the vessel wall and into the interstitial space. Nonspecific uptake by perivascu lar stromal cells such as TAMs [60] [61] [62] [63] can further limit the diffusion of nanotherapeutics. It is also noteworthy that mean tumour intercapillary distances generally range from approximately 80 to hundreds of micrometres [127] [128] [129] , presenting another obstacle to NPs reaching tumour cells that are further from vessels.
For enhanced tumour penetration, one possible solu tion is to tune the physicochemical properties of NPs to penetrate diffusional barriers in the interstitial matrix. Smaller NPs could more readily diffuse throughout the tumour tissue [130] [131] [132] , but very small particles (for exam ple, <5 nm) may be quickly cleared by renal filtration. Moreover, small NPs have a large surface area to volume ratio and a short diffusion distance for encapsulated drugs, limiting their drugcarrying and controlled release capabilities. Nanorods (15 nm × 54 nm) have also exhib ited more rapid tumour penetration than 35 nm nano spheres 114 , possibly related to their shorter dimension, although both have a 33-35 nm hydrodynamic diameter and nearly identical diffusion rates in water. In addition, surface modification with tumourspecific penetrating peptides, such as the cyclic peptide CRGDK/RGPD/EC (also called iRGD), has also been shown to substantially increase the depth of NP delivery into tumour paren chyma 133, 134 . Further systematic study of NP-TME inter actions through realtime in vivo imaging techniques, such as intravital microscopy 135 , may identify the optimal particle properties for rapid diffusion. TMEmodification approaches, such as degrading the tumour ECM and inhibiting the activity of tumourassociated fibroblasts to reduce their production of matrix components, which were previously overviewed 136 , could likewise assist NPs in permeating tumour tissues.
Recently, an alternative novel multistage delivery strategy has been proposed to address the penetration problem 137 . Smallmolecule drug conjugates (SMDCs) 138 and miniaturized biologic drug conjugates (mBDCs), including peptide-drug conjugates 139 , were developed to address the large size shortcoming of antibody-drug conjugates (ADCs), which limits their tumour tissue penetrability. SMDCs and mBDCs can also enhance retention and cellular uptake by tumours compared with free drug alone. However, their considerable drawbacks include poor PK, which may limit their tumour exposure and therapeutic impact. By incorporating SMDCs and mBDCs into controlledrelease polymeric NPs for multi step delivery to tumours, it may be possible to combine the superior PK and tumour accumulation of NPs with the deep penetration and specific tumour cell targeting of released SMDCs and mBDCs for optimal targeted cancer therapy 137 .
There have also been reports of similar multi stage delivery platforms 130, 140 in which very small NPs (for example, approximately 10 nm quantum dots) are first loaded into large particles, such as approxi mately 3.5 μm hemispherical mesoporous silicon 140 or approximately 100 nm gelatin NPs 130 . When the large particles reach the tumour vasculature or are exposed to the TME, the released smaller NPs can then readily diffuse throughout the interstitial space of the tumour. Other stimuli responsive multistage delivery platforms have recently been developed for various hardtotreat solid tumours 141, 142 . Cellular uptake and intracellular trafficking. Effective cell internalization may also have an important role in enhancing NP retention, EPR and therapeutic efficacy, as many nanomedicines act on intracellular targets. This is particularly true for biomacromolecule payloads such as those involved in the RNAi pathway (for example, siRNA and microRNA (miRNA)), which require cytosolic deliv ery for bioactivity [143] [144] [145] . To improve cellular uptake, one approach is to decorate the NPs with targeting ligands that recognize specific receptors on the tumour cell surface 9, 146, 147 (FIG. 2f) . Moreover, active targeting is of importance when tissue accumulation does not depend on EPR (for example, vascular targeting) 148 or when the delivery of therapeutic agents requires active transcytosis of physiological barriers such as the intestinal mucosa or the blood-brain barrier [149] [150] [151] . Since the concept of active NP targeting was introduced more than 30 years ago 152, 153 , a few examples have made their way into clinical trials 9 , including targeted liposomes (for example, HER2 (also known as ERBB2) singlechain variable fragment (scFv)targeted liposome (MM302) 154 ), the first targeted and controlledrelease polymeric NP (BIND014) 11 and the first targeted siRNA NP (CALAA01) 30 . Even with out targeting ligands, NPs can still be engineered for increased uptake by tumour cells by exploiting size and shapedependent cell internalization 155, 156 .
In addition, it may be important to investigate the effect of cancer cell mutations on NP internalization. Pancreatic cancer cells with KRAS mutations show ele vated macropinocytosis of proteins such as albumin, and the ability of extracellular albumin to enhance the prolif eration of cancer cells after glutamine starvation is also dependent on oncogenic KRAS expression 157 . This study indicates that macropinocytosis might enhance the uptake of drugs such as paclitaxel when it is bound to albumin, partly explaining the recent success of nab paclitaxel in treating advanced pancreatic cancer largely driven by oncogenic KRAS 158 . Whether such an oncogenic mutation effect also applies to NP endocytosis remains unclear. It should also be noted that our current understanding of NP-cell interactions is generally based on in vitro studies, which may not reflect the hetero geneity of tumour cells in vivo. Recent advances in high resolution cellular in vivo imaging methods have enabled the detailed analysis of singlecell PK and celltocell variability in tumours [159] [160] [161] [162] , and are expected to provide insights into NP interaction with tumour cells and the TME in vivo.
After internalization, NPs must either release their therapeutic payload for diffusion through the cellu lar compartments to reach the target, or be directed through intracellular trafficking pathways to release therapeutics in the appropriate subcellular location. For cytosolic delivery of biomacromolecules such as siRNA, NP endosomal escape is crucial. Cationic lipid, lipid like material and polymerbased NPs have shown great promise in siRNA delivery [163] [164] [165] . Notably, most RNAi nanotherapeutic agents in clinical trials for cancer treat ment are composed of liposomes or lipid NPs (TABLE 1) . Although these lipidbased NPs are currently not func tionalized with ligands for active targeting, targeted NP delivery could further enhance tumour accumulation and retention and cellular uptake of siRNA 144, 166 . Despite clinical trial success, the efficiency of lipid NPmediated siRNA release from endosomes remains low (1-2%) 167 , and approximately 70% of the internalized siRNA may undergo Niemann-Pick type C1mediated exocytosis 168 . Thus, alternative strategies will be necessary to develop NP platforms with highly efficient endosomal escape. Besides cytosolic delivery, targeting intracellular orga nelles such as the nucleus, mitochondria, endoplasmic reticulum and Golgi has also been pursued. Whereas some NPs have been developed for specific uptake by these subcellular compartments [169] [170] [171] [172] [173] [174] , the underlying barriers of organelle membranes to the transport of NPs need to be further explored.
Controlled drug release.
An equally important yet often overlooked consideration is that systemically adminis tered NPs may gradually release their payload during cir culation (FIG. 2 g ), such that longcirculating particles with slow tumour extravasation may hold relatively small pay loads by the time they reach the TME. Therefore, simul taneous consideration of drug release, NP PK and NP extravasation is required to achieve optimal outcomes.
We think that the design of optimal NP systems requires a deep understanding of several complex param eters: the interplay between NP PK and drug PK, between encapsulated drug and released drug in plasma, between drug C max and NP C max , between drug plasma AUC and NP plasma AUC; and factors that may differentially affect plasma versus tumour PK and AUC. Conventional smallmolecule drugs generally reach their plasma C max during the intravenous infusion period, followed by a reduction in plasma drug concentration. Similarly, for drugencapsulated controlledrelease NPs, C max will be reached during infusion, yet the plasma concentration of the released drug will in general be very low initially and progressively increase, reaching its C max after some period of NP circulation. Importantly, the drug C max achieved through release from NPs is unlikely to ever reach the levels achieved with intravenous administra tion of free drug. Therefore, drugassociated toxicities related to C max may be mitigated using NPs. On the other hand, plasma AUC will be relatively similar for free drug and NPreleased drug, with one key difference: the AUC of NPreleased drug will be generally broad and flat, whereas the AUC for free drug is likely to be peaked, with a tail. The implications are that although certain toxicities may be reduced with the use of NPs, the AUC related toxicity may be harder to overcome with NPs even though the total dose is released over a longer period of time. When drugs are delivered by NPs, the tumour PK and AUC are dramatically different from those of drugs given in the conventional form, in part because EPR results in differential tumour accumulation of NPs to a greater extent than free drugs and the drug released from NPs localized to tumours can lead to higher tumour drug concentrations over a longer period of time. Most publi cations demonstrate that NPs enhance delivery of drugs to tumours. A subset of studies show that over time, tumour drug C max , PK and/or AUC [175] [176] [177] [178] are improved compared with conventional dosage. However, these increases in tumour drug accumulation have not always translated into improved patient OS, begging several questions. Does the increase in tumour drug concen tration broadly occur in patients or is patient selection needed to identify the subpopulation likely to accumulate NPs? Is increased tumour dose universally beneficial for all drugs or does that depend on the drug?
To precisely control drug release, various stimuli responsive NPs have been developed and are summa rized in a recent review article 179 . In general, these NPs are designed to recognize subtle environmental changes associated with the TME and tumour cells (for exam ple, pH, redox state and enzymes) or to be activated by external stimuli (for example, heat, light, magnetic field or ultrasound), triggering the release of the payload (FIG. 2 g ). To some degree, external stimulation enables tailored drugrelease profiles with temporal and spa tial control. Thermosensitive liposomes (for example, the LD ThermoDox) for heatmediated drug release are the most advanced clinical stage platform to date. In 2013, ThermoDox failed to meet its primary end point of PFS in a phase III study for hepatocellular car cinoma, and is now undergoing a phase III study with OS as the primary end point (see 184 , among others. The clinical potential of these newer systems remains to be determined.
Overall, with continuous improvements in our understanding of the biological steps in systemic NP delivery, a myriad of new strategies have been developed for enhancing drug delivery to tumours and therapeu tic responses. As most of these results are from animal studies, further clinical validation is necessary.
Targeting the TME and the premetastatic niche As the TME has an important role in tumour develop ment, progression and metastasis and in the emergence of drug resistance, it has also been considered a target for cancer treatment 14, 15, 185 . As discussed above, TME modi fication also offers an alternative strategy for enhancing the tumour accumulation and penetration of NPs 107, 136 . Compared with cancer cells, one advantage of targeting nontumoural cells in the TME is that they are likely to be more genetically stable and thus less prone to develop drug resistance 185 . However, targeting nontumoural cells raises the challenge of achieving a therapeutic effect while minimizing toxicity to normal cells; how TME modification affects tumour growth and meta stasis needs more careful examination. Beyond the TME of the primary tumour, the environmental conditions required for metastatic cells to survive and proliferate have also received considerable attention in the development of new therapeutic avenues 186 . Early interference with the formation of the premetastatic niche may be particu larly beneficial in the treatment of malignancies that tend to metastasize.
Tumour vasculature. Much effort has focused on NPmediated selective drug delivery to the tumour vasculature (FIG. 4a) , which is crucial to tumour growth and metastasis 148 . This is commonly achieved by coat ing NPs with ligands that bind specifically to over expressed receptors such as α v β 3 integrin 187 on the surface of tumour endothelial cells. In vivo studies in mice revealed that inhibiting angiogenesis can cause regression of established tumours or suppression of meta stasis 188, 189 . Besides targeted NPs, several non targeted cationic lipid or polymeric NP platforms have been designed for prefer ential delivery of siRNA to vascular endothelium [190] [191] [192] . A recent unique formula tion called 7C1 specifically reduced the expression of target endothelial genes at low siRNA doses without substantially reducing their expression in pulmonary immune cells, hepatocytes or peritoneal immune cells 192 . By silencing VEGF receptor 1 (VEGFR1) or deltalike protein 4 (DLL4) involved in angiogenesis, 7C1 RNAi NPs reduced growth and metastasis of Lewis lung carci noma in mouse models in vivo 192 . This interesting system could also be used to study how interactions with serum proteins direct nanomaterials to endothelial cells in vivo.
Stromal cells.
Targeting stromal cells such as tumour associated fibroblasts and macrophages has also been proposed for cancer treatment (FIG. 4a) . A unique docetaxelconjugated NP platform called Cellax sig nificantly depleted αsmooth muscle actin (αSMA) expressing fibroblasts, reducing tumour ECM and IFP, increasing vascular permeability and suppressing meta stasis 193 . This effect is presumably through the adsorption of serum albumin on Cellax, followed by specific inter action with αSMA + fibroblasts that also express elevated levels of the albuminbinding protein, secreted acidic cysteinerich glycoprotein (SPARC). Differentiation of TAMs to a protumorigenic or immunosuppressive (M2like) phenotype has commonly been associated with tumour progression and poor patient outcome 194 . By inhibiting the activity of signal transducer and activator of transcription 3 (STAT3), hydrazinocurcuminloaded NPs can 'reeducate' TAMs to transform from an M2like into an antitumorigenic M1 phenotype for inhibited tumour growth 195 . PEGsheddable, mannosemodified NPs have also been developed to efficiently target TAMs that have elevated expression of mannose receptors, while minimizing uptake by macrophages of the MPS 196 . Furthermore, NPbased codelivery of multiple agents targeting both TME and tumour cells has produced syn ergistic anticancer effects [197] [198] [199] . However, TMEtargeting strategies must be pursued with care, as tumour stroma exhibits bipolar activity in tumorigenesis 200 .
Metastatic microenvironment. NP delivery to the major sites of metastasis (for example, lungs, liver, lymph nodes, brain and bone) and metastatic tumour cells themselves have been comprehensively discussed Nature Reviews | Cancer elsewhere 201 . A newly developed system of polymeric micelles formulated from polymer-drug conjugates has shown promising therapeutic efficacy in a mouse model of colon cancer with lung metastasis 202 , and in a pilot study of one patient with castrationresist ant prostate cancer with lung and bone metastases 203 . Comparatively little effort has been devoted to exploiting nanotechnology to modify the premetastatic microen vironmental niche and suppress tumour growth. In a recent study, a bonehoming polymeric NP platform was engineered for spatiotemporally controlled deliv ery of therapeutic agents 204 (FIG. 4b) . After pretreatment with alendronateconjugated, bortezomibloaded poly meric NPs, mice showed significantly slower myeloma tumour growth and prolonged survival. The application of such pretreatment strategies for protecting the organs vulnerable to metastasis could be accelerated by reveal ing which microenvironmental factors control the intra vasation, adhesion and growth of metastatic tumour cells and how this is achieved.
Challenges in clinical translation
Controllable and reproducible synthesis. The determi nation of optimal physicochemical parameters is cru cial for the successful development of therapeutic NPs. A considerable amount has been learnt regarding indi vidual factors that can confer effective immune evasion, tumour extravasation and diffusion, cell targeting and internalization, and controlled drug release 65, 66, 78, 205, 206 . Nevertheless, systematic parallel screening of the myr iad of NP properties remains difficult, owing to the challenge of rapid, precise and reproducible synthesis of NP libraries with distinct features. Compared with traditional bulk techniques, which generally form NPs with high polydispersity, microfluidic technologies have recently attracted attention for highspeed selfassembly of NPs with narrower size distribution, tunable physical and chemical characteristics and greater batchtobatch reproducibility [207] [208] [209] [210] [211] . Similarly, particle replication in nonwetting template (PRINT) technology has enabled the synthesis of monodisperse NPs with precise control over size, shape, chemical composition, drug loading and surface properties 212, 213 . Such advances could even tually facilitate NP discovery, analogous to the way highthroughput screening of small molecules advanced drug discovery.
Evaluation and screening.
With the rapid emergence of NPs composed of novel biomaterials or nanostructures, in vitro evaluation is important to identify biocompati ble candidates before animal testing is pursued. In vitro assays can also improve our understanding of NP-cell interactions. However, as conventional in vitro models using cells cultured in multiwell plates lack the complex ity of biological tissues and control over fluid flow, such platforms may not capture the intricate interplay of NPs with physiological barriers. Recent efforts to develop bio mimetic 'organ/tumouronachip' tools [214] [215] [216] may avoid the limitations of current in vitro models. The incorpora tion of tumourlike spheroids into a microfluidic chan nel could offer insights into the effects of interstitial flow, cell binding and particle size on NP accumulation and diffusion 216 . Comparison of NP behaviours in such chip systems with animal models may offer a preview of the potential of these biomimetic microdevices.
To assess in vivo NP performance (for example, PK, biodistribution, efficacy and safety), the use of ani mal models is obligatory. Whereas some studies have demonstrated PK scaling across different species (includ ing humans) for different nano therapeutics [11] [12] [13] 32 , one wellrecognized obstacle is the discrepancy between the efficacies obtained in preclinical studies and the outcomes from clinical trials, in large part owing to the lack of tumour models that can recapitulate human cancers 217, 218 . Diverse animal models are currently avail able, including cell linebased subcutaneous and ortho topic xenografts, patientderived xenografts (PDXs) and genetically engineered mouse models (GEMMs). However, no single model can fully reproduce all aspects of human malignancy, and EPR is generally more consistent in animal models than in cancer patients 9 . Furthermore, considering the major contribution of tumour metastases to cancer mortality, models of human tumour metastasis will be invaluable for the evaluation of EPR and NP penetration and targeting in metastatic tis sues compared with primary tumours. The translation of nanotherapeutics may be greatly improved by the devel opment of animal models that mimic closely the hetero geneity and anatomical histology of human tumours, such as high fidelity PDXs 219 , humanized mouse models 220 and GEMMs with aggressive metastasis 221 .
Scalable manufacturing. Another challenge to clinical development stems from the escalating complexity in the chemistry, manufacturing and controls (CMC) and good manufacturing practice (GMP) requirements as NP technologies transition from preclinical to clinical devel opment, subsequent commercialization and beyond, as long as the product is on the market. Although the shared goal of CMC and GMP is to assure that a product consistently meets a predetermined standard of quality, they involve different but overlapping approaches and regulation. The scaleup of simple NPs, including lipo somes and polymeric systems with smallmolecule APIs that have desirable physicochemical properties, can be achieved using manufacturing unit operations readily available and widely used in the pharmaceutical indus try. The scaleup of more complex nanomedicines may pose additional CMC and GMP challenges, and require modification of existing unit operations or development of novel manufacturing processes. Examples include nanomedicines that integrate biological targeting lig ands or biological components, carry a combination of two or more therapeutics, are formulated through layerbylayer assembly or comprise multiple functional units such as theranostics or multistage systems. In general, largescale and reproducible synthesis will be more difficult when NP formulation involves multiple steps or complicated technologies. Indeed, the transition from laboratory to clinic is nearly always accompanied by the optimization of formulation param eters, or even a change in formulation methods, making forward thinking of scaleup considerations an impor tant aspect of early NP design and engineering. The PRINT technology is amenable to reproducible fabri cation of NPs 213 , yet scaling to kilograms remains to be demonstrated. A coaxial turbulent jet mixer technology, which has the advantages of homogeneity, reproducibil ity and tunability normally accessible only in microscale mixing techniques such as microfluidics, has recently been developed for mass production of polymeric NPs (potential of ~3 kg/day per channel) 222 . Although today the mainstay of NP manufacturing remains bulk synthe sis, robust and versatile approaches such as PRINT and turbulent jet mixer technologies, which can prepare NPs at throughputs suitable for industrialscale production, may accelerate clinical translation.
Conclusion
Like most other scientific advances that have revolu tionized medicine over the past decades, cancer nano medicine must also mature before its full impact can be realized. Improving our understanding of tumour heterogeneity and identifying EPR markers will ena ble selection of patients maximally responsive to nano therapies. A full understanding of nano-bio inter actions, systemic transport of NPs to tumour cells and targeting of NPs to the TME or premetastatic niche will lead to safer and more efficacious nano therapeutics. Addressing the challenges of controllable, reproduci ble and scalable NP synthesis, as well as NP screening and evaluation, will facilitate clinical development. Although most approved nano medicines have used existing drugs as payloads, we expect the next genera tion of nanomedicines to increasingly incorporate new molecular entities (for example, kinase inhibitors 24 ) and novel classes of therapeutic agent (for example, siRNA, mRNA and gene editing).
In summary, we are rapidly acquiring a much deeper understanding of the challenges and opportunities presented by cancer nanomedicine. This Review has explored the importance of the convergence of nano technology and tumour biology for more successful development and clinical translation of nanotherapeutics. We expect that nanomedicines will shift the paradigm of cancer treatment, and that the true goal of cancer nano medicine -dramatic improvement in patient survival -will become a reality in the foreseeable future.
